Core Insights - Huamei Haolian has completed a multi-hundred million RMB Series D financing round, led by Yifeng Capital, Yahui Long, Ventech China, and Fengqiao Capital, with participation from Dongfang Guozi, Jinsha River Ventures, and Tongji Alumni Fund. The funds will be used for clinical advancement and commercialization of core products [2]. Company Overview - Huamei Haolian Medical Technology (Beijing) Co., Ltd. was established in 2017, headquartered in Suzhou with an operational center in Beijing. The company positions itself as an AI digital health service technology group, providing health management service solutions covering the entire lifecycle from pre-diagnosis to post-diagnosis for clients in insurance, banking, and enterprises [3]. - The company has branches in multiple cities including Shanghai, Guangzhou, Hainan, Yinchuan, Hangzhou, and Hefei, as well as in the United States, serving nearly 300 B-end clients and covering over 56 million end users [3]. Product and Technology - The main products include AI intelligent applications, a medical service network, and an AI product system. The company has developed algorithms for "precise medical treatment" and "traditional Chinese medicine consultation," which have been officially filed in the precision medical field [8]. - The company has established a service network covering 1,650 top-tier hospitals nationwide and links with 8 international medical systems and 3,000 international experts [8]. - Diverse health management products include "AI General Practitioner," "AI Precise Medical Treatment," "AI Health Report Interpretation," and community healthcare assistants aimed at grassroots medical institutions [8]. Financing History - The financing history of Huamei Haolian includes several rounds, with the latest being a Series D round raising hundreds of millions of RMB. Previous rounds include a C+ round in September 2025 and a C round in July 2024, with various venture capital firms participating [9]. Patent Information - The company holds several patents, including a digital-based smart elderly care monitoring system and a smart medical response method based on big data, all of which have been authorized [10].

Core Insights - The company, Laolai Health Technology Group, is a leading enterprise in the digital health service sector, focusing on enhancing the quality of life for the elderly through technology [1] - The company has developed a comprehensive service platform that connects over 2.5 billion elderly individuals with healthcare resources, including 34 million registered users and over 80,000 daily active users [1] Group 1 - The company has established a SaaS model for kidney disease management, addressing key challenges such as insurance regulation difficulties, low medical efficiency, and weak patient follow-up [3] - The "Kidney Care" AI management assistant has been launched in collaboration with local healthcare institutions, improving patient management and satisfaction while reducing operational costs for medical facilities [3] - The AI-driven solution utilizes real-time health data collection and dynamic health profiling to enhance follow-up efficiency and service verification for insurance departments [3] Group 2 - The success of the "Kidney Care" initiative has created a replicable model for chronic disease management, with potential expansion into other chronic conditions like diabetes and hypertension [4] - The company aims to leverage its extensive resources in social security and health insurance to support the intelligent upgrade of medical security during the 14th Five-Year Plan [4] - Laolai Health is committed to continuous innovation in healthcare services, striving to provide efficient and precise health management solutions for millions of families [4]